TTR
Transthyretin
As of the edition of 20 October 2026, TTR (transthyretin, UniProt P02766) has 13 drugs tested at it and 9 companies on the list, 2 on route A and 5 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P02766
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 496
- Disease areas
- Nutrition and metabolism; Nervous system; Inherited and neonatal; Heart and blood vessels; Mental health
- Registered trials of its drugs
- 84
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 9 |
| Went quiet | 2 |
| Stopped | 1 |
| Status not established | 1 |
| Total | 13 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tafamidis | Marketed | Phase 4 | Ends 2035 |
| Acoramidis | Marketed | Phase 4 | Ends 2038 |
| Eplontersen | Marketed | Phase 3 | none listed |
| Patisiran | Marketed | Phase 3 | none listed |
| Inotersen | Marketed | Phase 4 | Ends 2031 |
| Revusiran | Went quiet | Phase 2 | none listed |
| Vutrisiran | Marketed | Phase 3 | none listed |
| NI006 | Status not established | Phase 1 | none listed |
| PRX004 | Stopped | Phase 1 | none listed |
| SOM0226 | Went quiet | Phase 2 | none listed |
| Eplontersen sodium | Marketed | No phase stated | Ends 2034 |
| Patisiran sodium | Marketed | No phase stated | Ends 2035 |
12 of 13 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 5 |
| Engaged | 1 |
| Undetermined | 1 |
| Total on the list | 9 |
| Company | Route |
|---|---|
| AstraZeneca | Route B |
| Pfizer | Route B |
| Bridgebio Pharma | Route B |
The other 6 companies at TTR
In the product9 companies in all; 6 are not named here, and no score is.
See the 9 companies at TTR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.